Galena Biopharma is focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics.
Abstral, the Company's sublingual formulation of fentanyl citrate, provides statistically significant and rapid relief of breakthrough cancer pain for patients with all types of cancer, providing improvements in pain-related daily function and patient quality of life. Currently in clinical trials, though, is NeuVax (neliepimut-S or E75), one of Galena's cancer immunotherapy treatments.
The immunotherapy of cancer aims at specifically activating cells of the immune system, especially the so-called cytotoxic T-cells ("killer T-cells") to seek out and eliminate tumor cells while not harming healthy tissue.
NeuVax works by turning on the immune system. It recruits the main components of the cellular immune system to fight cancer by presentation of a T-cell peptide epitope in the context of the peptide-HLA-T-cell receptor complex-effectively using the patient's own immune system (i.e., nature's own defense system against foreign or harmful germs) for the treatment of the cancer.
Folate Binding Protein-E39 (NYSE:FBP), another Galena treatment, is a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. It has very limited tissue distribution and expression in non-malignant tissue making it an ideal immunotherapy target.
The FBP vaccine consists of the E39 peptide derived from the folate binding protein combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF), and is specifically used to treat endometrial and ovarian cancers.
Ideally, a vaccine is specific and should only affect the cancer cells and not attack normal cells. Cancer immunotherapy causes the immune system to make antibodies to one or several specific antigens, and/or make killer T cells to attack cancer cells that express those antigens. Similar to prophylactic vaccines, Galena's cancer immunotherapies can be delivered with adjuvants, which are designed to boost the immune response.
For more information, visit the website at galenabiopharma.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com